STAT3 Inhibition in Cancer: A Review of Emerging Therapeutics
DOI:
https://doi.org/10.62382/jcbt.v2i2.63Keywords:
STAT3 inhibition, Cancer pathways, Small-molecule inhibitors, Targeted therapyAbstract
Abnormal signal transducer and transcriptional activator (STAT3) activation occurs in many human tumors. Therefore, targeting STAT3 signaling has emerged as a promising therapeutic approach for treating many cancers. In addition, studies using genetic and pharmacological agents to alter the activity of STAT3 provide significant evidence for the role of STAT3 dysfunction. in malignant transformation and cancer, confirming STAT3 as a novel cancer target. In this review, we provide an outline of the importance of targeting the STAT3 signaling pathway, the mechanism of action of inhibitors, and the current development of STAT3-targeted drug therapy. We also summarize the efforts to provide new insights into the translation of STAT3 in cancer and may contribute to better treatments for these malignancies. The main purpose of this review is to provide a general framework for the development of STAT3 inhibitors and a discussion of the inhibition mechanisms developed.
Downloads
References
Darnell Jr JE. STATs and gene regulation. Science. 1997, 277(5332), 1630-1635. DOI: 10.1126/science.277.5332.1630
Turkson J, Zhang SM, Palmer J, Kay H, Stanko J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Molecular Cancer Therapeutics. 2004, 3(12), 1533-1542. DOI： 10.1158/1535-7163.1533.3.12
Schröder M, Kroeger KM, Volk HD, Eidne KA, Grütz G. Preassociation of nonactivated STAT3 molecules demonstrated in living cells using bioluminescence resonance energy transfer: a new model of STAT activation? Journal of Leukocyte Blology. 2004, 75(5), 792-797. DOI: 10.1189/jlb.1003496
Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Seminars in Cell & Developmental Biology. 2008, 19(4), 329-340. DOI: 10.1016/j.semcdb.2008.07.003
Cai LY, Zhang GM, Tong XJ, You Q, An Y, et al. Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2010, 148(1), 73-80. DOI: 10.1016/j.ejogrb.2009.09.018
Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995, 269(5220), 81-83. DOI: 10.1126/science.7541555
Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opinion on Therapeutic Targets. 2004, 8(5), 409-422. DOI: 10.1517/14728222.8.5.409
Yu H, Jove R. The STATs of cancer—new molecular targets come of age. Nature Reviews. Cancer. 2004, 4(2), 97-105. DOI: 10.1038/nrc1275
Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000, 19(21), 2474-2488. DOI: 10.1038/sj.onc.1203527
Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Research. 2008, 18(2), 254-267. DOI: 10.1038/cr.2008.18
Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem. 2008, 3(8), 1159. DOI: 10.1002/cmdc.200800123
Wang SM, Yang DJ, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Seminars in Oncology. 2003, 30, 133-142. DOI: 10.1053/j.seminoncol.2003.08.015
Mohammad RM, Wang SM, Aboukameel A, Chen B, Wu XH, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(−)-gossypol] against diffuse large cell lymphoma. Molecular Cancer Therapeutics. 2005, 4(1), 13-21. DOI: 10.1158/1535-7163.13.4.1
Yang XJ, Xu L, Yang L, Xu SH. Research progress of STAT3-based dual inhibitors for cancer therapy. Bioorganic & Medicinal Chemistry. 2023, 91, 117382. DOI: 10.1016/j.bmc.2023.117382
Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. The Journal of Biological Chemistry. 2001, 276(48), 45443-45455. DOI: 10.1074/jbc.M107527200
Yang LH, Lin C, Xu LY, Lin JY, Zhao CG, et al. Novel activators and small-molecule inhibitors of STAT3 in cancer. Cytokine & Growth Factor Reviews. 2019, 49, 10-22. DOI: 10.1016/j.cytogfr.2019.10.005
Thilakasiri PS, Dmello RS, Nero TL, Parker MW, Ernst M, et al. Repurposing of drugs as STAT3 inhibitors for cancer therapy. Seminars in Cancer Biology. 2021, 31-46. DOI: 10.1016/j.semcancer.2019.09.022
Turkson J, Zhang SM, Mora LB, Burns A, Sebti S, et al. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. The Journal of Biological Chemistry. 2005, 280(38), 32979-32988. DOI: 10.1074/jbc.M502694200
Weidler M, Rether J, Anke T, Erkel G. Inhibition of interleukin-6 signaling by galiellalactone. FEBS Letters. 2000, 484(1), 1-6. DOI: 10.1016/s0014-5793(00)02115-3
Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, et al. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Molecular Cancer Research : MCR. 2004, 2(3), 170-182. DOI: 10.1158/1541-7786.170.2.3
Buerger C, Nagel-Wolfrum K, Kunz C, Wittig I, Butz K, et al. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. The Journal of Biological Chemistry. 2003, 278(39), 37610-37621. DOI: 10.1074/jbc.M301629200
Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2005, 102(13), 4700-4705. DOI: 10.1073/pnas.0409894102
Chen CL, Loy A, Cen L, Chan C, Hsieh FC, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer. 2007, 7, 111. DOI: 10.1186/1471-2407-7-111
Bhasin D, Cisek K, Pandharkar T, Regan N, Li CL, et al. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorganic & Medicinal Chemistry Letters. 2008, 18(1), 391-395. DOI: 10.1016/j.bmcl.2007.10.031
Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer. Annals of the New York Academy of Sciences. 2006, 1091, 151-169. DOI: 10.1196/annals.1378.063
Sau S, Mondal SK, Kashaw SK, Iyer AK, Banerjee R. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug. Molecular and Cellular Biochemistry. 2017, 436(1-2), 119-136. DOI: 10.1007/s11010-017-3084-z
Zhang XL, Zhang J, Wang LH, Wei HM, Tian ZG. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer. 2007, 7, 149. DOI: 10.1186/1471-2407-7-149
Zhao M, Jiang B, Gao FH. Small molecule inhibitors of STAT3 for cancer therapy. Current Medicinal Chemistry. 2011, 18(26), 4012-4018. DOI: 10.2174/092986711796957284
Siddiquee K, Zhang SM, Guida WC, Blaskovich MA, Greedy B, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the United States of America. 2007, 104(18), 7391-7396. DOI: 10.1073/pnas.0609757104
Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chemistry & Biology. 2006, 13(11), 1235-1242. DOI: 10.1016/j.chembiol.2006.09.018
Hao WS, Hu YB, Niu CS, Huang XY, Chang CPB, et al. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorganic & Medicinal Chemistry Letters. 2008, 18(18), 4988-4992. DOI: 10.1016/j.bmcl.2008.08.032
Lee C, Cheung ST. STAT3: an emerging therapeutic target for hepatocellular carcinoma. Cancers. 2019, 11(11), 1646. DOI: 10.3390/cancers11111646
Harada D, Takigawa N, Kiura K. The role of STAT3 in non-small cell lung cancer. Cancers. 2014, 6(2), 708-722. DOI: 10.3390/cancers6020708
Huang W, Dong Z, Chen Y, Wang F, Wang CJ, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2016, 35(6), 783-792. DOI: 10.1038/onc.2015.419
Tolomeo M, Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. International Journal of Molecular Sciences. 2021, 22(2), 603. DOI: 10.3390/ijms22020603
Yu WY, Xiao H, Lin J, Li CL. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. Journal of Medicinal Chemistry. 2013, 56(11), 4402-4412. DOI: 10.1021/jm400080c
Masciocchi D, Villa S, Meneghetti F, Pedretti A, Barlocco D, et al. Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors. Medicinal Chemistry Communication. 2012, 3(5), 592-599. DOI: 10.1039/C2MD20018J
Lakshmanan K, T K P, K Pai SR, Rajagopal K, Byran G. Discovery of potential inhibitors for stat3: ligand based 3D pharmacophore, virtual screening, molecular docking, dynamic studies and in vitro evaluation. Journal of Biomolecular Structure & Dynamics. 2022, 40(21), 11320-11338. DOI: 10.1080/07391102.2021.1957717
Jing NJ, Li YD, Xu XJ, Sha W, Li P, et al. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA and Cell Biology. 2003, 22(11), 685-696. DOI: 10.1089/104454903770946665
Rafiq H, Hu J, Hakami MA, Hazazi A, Alamri MA, et al. Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations. Scientific Reports. 2023, 13(1), 20147. DOI: 10.1038/s41598-023-46193-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Cancer Biomoleculars and Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
